The scientific community has made significant strides in recent years towards developing innovative methods for producing and analyzing complex molecules. In an exciting breakthrough, researchers from Ca’ Foscari University of Venice, along with international collaborators, have successfully harnessed the potential of brewer’s yeast to create miniature factories that produce macrocyclic peptides – promising drugs with high therapeutic value.

Macrocyclic peptides are a class of molecules that offer precision targeting, stability, and safety, making them an attractive alternative to traditional drugs. However, conventional methods for discovering and testing these peptides have been complex, slow, and environmentally unfriendly. To overcome these limitations, the researchers engineered brewer’s yeast cells to individually produce different macrocyclic peptides.

Each yeast cell acts as a tiny factory that lights up when producing the compound, allowing scientists to swiftly identify promising peptides. Using advanced fluorescence-based techniques, the team screened billions of micro-factories in just a few hours – a process significantly faster and more ecofriendly than existing methods.

Lead author Sara Linciano explained the innovative approach: “We manipulated yeast cells so that each one functions as a ‘micro-factory’ that becomes fluorescent when producing a specific compound. This allowed us to analyze 100 million different peptides rapidly and effectively.”

The study’s co-leader, Ylenia Mazzocato, highlighted the sustainability of their approach: “By exploiting the natural machinery of yeast, we produce peptide molecules that are biocompatible and biodegradable, making them safe for health and the environment – a truly ‘green pharma’ approach.”

The researchers also demonstrated the excellent binding properties of these peptides using X-ray crystallography. This new method offers significant advancements for drug discovery, especially for challenging targets that conventional drugs cannot easily address.

As Alessandro Angelini, associate professor and study coordinator, emphasized: “We are pushing the boundaries of this technology to create macrocyclic peptides that can deliver advanced therapies directly to specific cells, potentially revolutionising treatments. This could greatly benefit patient health and have substantial scientific and economic impacts.”

This work was part of the National Recovery and Resilience Plan (PNRR), supported by the European Union’s Next Generation EU initiative. The team involved multidisciplinary experts from Ca’ Foscari University of Venice, Kyoto Institute of Technology, Chinese Academy of Sciences, University of Padova, and École Polytechnique Fédérale de Lausanne.

Part of this technology has already been patented by Ca’ Foscari and was recently acquired by the startup Arzanya S.r.l. As Angelini concluded: “Seeing our technology gain international recognition makes me proud. I hope Arzanya S.r.l. can provide our talented young researchers with the opportunity to pursue their passions here in Italy, without necessarily needing to move abroad.”

The devastating effects of spinal cord injuries have left millions without hope for recovery. However, groundbreaking research at Waipapa Taumata Rau, University of Auckland, has sparked new possibilities. Scientists have successfully used an implantable electronic device to restore movement in rats with spinal cord injuries, offering a glimmer of hope for humans and their pets.

Spinal cord injuries disrupt the communication between the brain and body, resulting in a loss of function. Unlike cuts on the skin, which typically heal on their own, the spinal cord does not regenerate effectively, making these injuries currently incurable. However, researchers have harnessed the same electrical guidance system that naturally occurs before birth to encourage nerve tissue growth along the spinal cord.

Lead researcher Dr. Bruce Harland explains, “We developed an ultra-thin implant designed to sit directly on the spinal cord, precisely positioned over the injury site in rats.” The device delivers a carefully controlled electrical current across the injury site, aiming to stimulate healing and restore lost functions.

In a 12-week study, rats that received daily electric field treatment showed improved movement and responded more quickly to gentle touch compared to those who did not. This indicates that the treatment supported recovery of both movement and sensation, with no signs of inflammation or damage to the spinal cord.

The new study, published in Nature Communications, is a result of a partnership between the University of Auckland and Chalmers University of Technology in Sweden. Long-term, the goal is to transform this technology into a medical device that could benefit people living with life-changing spinal-cord injuries.

“This study offers an exciting proof of concept showing that electric field treatment can support recovery after spinal cord injury,” says doctoral student Lukas Matter from Chalmers University. The next step is to explore how different doses and treatment regimens affect recovery, to discover the most effective recipe for spinal-cord repair.

The scientific community has made another groundbreaking discovery that reveals how our beloved morning coffee might be doing more than just waking us up. A recent study conducted by researchers at Queen Mary University of London’s Cenfre for Molecular Cell Biology sheds light on the potential anti-ageing properties of caffeine, the world’s most popular neuroactive compound.

The research, published in the journal Microbial Cell, delves into the intricate mechanisms within our cells and how they respond to stress and nutrient availability. The scientists used a single-celled organism called fission yeast as a model to understand how caffeine affects ageing at a cellular level.

One of the key findings was that caffeine doesn’t act directly on the growth regulator called TOR (Target of Rapamycin), which is responsible for controlling energy and stress responses in living things for over 500 million years. Instead, it works by activating another crucial system called AMPK, a cellular fuel gauge that is evolutionarily conserved in yeast and humans.

“When your cells are low on energy, AMPK kicks in to help them cope,” explains Dr Charalampos (Babis) Rallis, Reader in Genetics, Genomics, and Fundamental Cell Biology at Queen Mary University of London, the study’s senior author. “And our results show that caffeine helps flip that switch.”

The implications of this discovery are significant, as AMPK is also the target of metformin, a common diabetes drug being studied for its potential to extend human lifespan together with rapamycin. The researchers demonstrated using their yeast model that caffeine’s effect on AMPK influences how cells grow, repair their DNA, and respond to stress – all of which are tied to ageing and disease.

These findings open up exciting possibilities for future research into how we might trigger these effects more directly – with diet, lifestyle, or new medicines. So, the next time you reach for your coffee, remember that it might be doing more than just boosting your focus – it could also be giving your cells a helping hand in slowing down your ageing process.